- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Astellas UK admitted multiple promotional items referenced two medicines but included prescribing information for only one. The Panel ruled breaches of Clauses…
A GP alleged inappropriate closeness between a representative and a GP partner, access issues, and possible funding of a practice barbecue. The…
ViiV admitted a February 2015 journal issue carried a 2-page Triumeq ad plus a belly band wrap, exceeding the Code’s 2-page limit…
AstraZeneca challenged Chiesi’s Fostair leavepiece headline “for an extra fine day”. PMCPA ruled it ambiguous, misleading and unsubstantiated (Clauses 7.2, 7.4). Wider…
A rheumatologist complained about a Pfizer rep’s conduct, including an alleged ITU patient on a competitor drug. On appeal, the patient was…
A public complaint alleged GSK failed to disclose Benlysta trial results per the ABPI Code. The Panel found the “missing” evaluable trial…
A hospital poster recruiting for the CODA trial (“Once daily Asacol”) prompted patients to request once-daily Asacol. PMCPA found P&G only provided…
Baxter admitted a representative did not take all required ABPI representative exam modules within 12 months of starting. The PMCPA ruled a…
Janssen admitted Code breaches after Trevicta two-page journal ads omitted the required reference to where prescribing information (overleaf) could be found and…
A Spiriva journal ad and a rep training/HP slide deck implied COPD exacerbation reduction as a primary reason to prescribe, without clearly…
Anonymous complainant alleged an unannounced home visit by a third-party nurse funded by BMS for Orencia support. Panel found insufficient evidence to…
Anonymous complaint alleged coercive funding and audit-driven switching via a nurse-led consultancy. Panel found no evidence Lilly funded audits or used sponsorship…
A nurse complained about a Remsima switch email. PMCPA found an exaggerated UK-wide “re-investing savings” claim was misleading/unsubstantiated and the “Don’t get…
PMCPA reviewed whether Novo Nordisk failed to disclose Ryzodeg trial results on time. Panel found UK Code scope issues for non-UK trials…
AbbVie admitted a first-time pharma representative did not take the required exam within 1 year and did not pass within 2 years.…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.